MedTrace Logo

Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators

NCT06672952 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-12-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the dose-dependent effects of glucosyl-hesperidin (CITRAPEAK) supplementation on exercise performance, recovery indicators, blood flow, cognitive function, mood, sleep, and fuel utilization in recreationally active adults.

Conditions

  • Exercise Performance
  • Exercise Recovery
  • Cognitive Function
  • Nitric Oxide
  • Blood Flow
  • Endurance Exercise

Interventions

DIETARY_SUPPLEMENT

400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation

The active intervention consists of 400 mg of glucosyl-hesperidin (CITRAPEAK®) in capsule form.

DIETARY_SUPPLEMENT

Placebo

The placebo intervention consists of 400 mg/day of cellulose in capsule form, matching the appearance and dosage of active interventions.

DIETARY_SUPPLEMENT

200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation

The active intervention includes 200 mg of glucosyl-hesperidin (CITRAPEAK®) and an additional 200 mg of cellulose in capsule form.

Sponsors & Collaborators

  • Increnovo, LLC

    collaborator INDUSTRY

  • Lindenwood University

    lead OTHER

Principal Investigators

  • Chad M Kerksick, PhD · Lindenwood University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-15
Primary Completion
2026-01-01
Completion
2026-01-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06672952 on ClinicalTrials.gov